Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31538290 | 0.85 | TRPA1 (0.32) | GAPDHTRPA1DDAH1MAPTLTB4R | |
| SCHEMBL1829186 | 0.78 | GAPDH (0.36) | GAPDHTRPA1DDAH1MAPTLTB4R | |
| SCHEMBL1813771 | 0.77 | GAPDH (0.31) | GAPDH | |
| SCHEMBL16167303 | 0.76 | TSHR (0.38) | GAPDHTRPA1DDAH1MAPTTSHR | |
| SCHEMBL16167304 | 0.76 | TSHR (0.38) | GAPDHTRPA1DDAH1MAPTTSHR | |
| SCHEMBL1815209 | 0.75 | GAPDH (0.33) | GAPDHTRPA1DDAH1MAPTACHE | |
| SCHEMBL1659273 | 0.75 | TSHR (0.36) | GAPDHTRPA1DDAH1MAPTACHE | |
| SCHEMBL1659272 | 0.75 | TSHR (0.36) | GAPDHTRPA1DDAH1MAPTACHE | |
| SCHEMBL31538319 | 0.72 | TSHR (0.40) | GAPDHTRPA1DDAH1MAPTLTB4R | |
| SCHEMBL1785949 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105409-A1 | Anticancer Compounds | PHARMA MAR, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105409-A1 | Anticancer Compounds | MCL1, TP53, BCL2A1 | GAPDH 685/4885TRPA1 3717/4885DDAH1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.